Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.42 |
| ▸ | CPB1 | P15086 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18342270 | 1.00 | PDE4B (0.47) | PDE4BSTSUSP30P2RX7CPB1 | |
| SCHEMBL20479586 | 1.00 | PDE4B (0.47) | PDE4BSTSUSP30P2RX7CPB1 | |
| SCHEMBL20479584 | 1.00 | PDE4B (0.47) | PDE4BSTSUSP30P2RX7CPB1 | |
| SCHEMBL16667797 | 0.92 | STS (0.48) | PDE4BSTSUSP30P2RX7CPB1 | |
| SCHEMBL16676906 | 0.92 | STS (0.48) | PDE4BSTSUSP30P2RX7CPB1 | |
| SCHEMBL16667796 | 0.92 | STS (0.48) | PDE4BSTSUSP30P2RX7CPB1 | |
| SCHEMBL13737268 | 0.88 | PDE4B (0.50) | PDE4BSTSUSP30CPB1SYK | |
| SCHEMBL13737266 | 0.88 | PDE4B (0.50) | PDE4BSTSUSP30CPB1SYK | |
| SCHEMBL4374791 | 0.88 | CPB1 (0.46) | CPB1CTSKCA1CA2ACHE | |
| SCHEMBL20479939 | 0.88 | CPB1 (0.46) | CPB1CTSKCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044068-B2 | Aminopyrrolidine compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044068-B2 | Aminopyrrolidine compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291940-A1 | AMINOPYRROLIDINE COMPOUND | MC4R, MC5R, MC2R | PDE4B 805/4885STS 4690/4885USP30 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.